ADC Therapeutics (ADCT) Q3 2026 earnings review
ADC Therapeutics extends its cash til 2029, diluting shareholders
ADC Therapeutics, the Swiss maker of blood cancer drug Zynlonta, bought itself time through deep cost cuts and a balance sheet overhaul while its existing commercial business stayed range-bound. Third-quarter product sales rose 33% from a weak year-ago period to $21 million, staying inside the same quarterly band seen for two years. Chief executive Ameet Mallik completed an October refinancing that cut term debt to $50 million and extended the cash outlook into 2029.
| Zynlonta product sales | $21.0M +33% from a year ago (+13% from last quarter) |
|---|---|
| Operating expenses, excluding one-offs | $32.0M -29% from a year ago |
| Quarter-end cash | $189.2M $196M pro forma after October financing |
| Cash runway outlook | Into 2029 Extended from at least into 2028 |
⚖️ Verdict: 🟢 Bullish
The story got better because the October debt paydown, covenant removal, and lower research spending took near-term financing risk off the table through 2029. Updated data from 97 patients in the LOTIS-7 combination study also kept response rates near 89% ahead of December's medical meeting. The bad news: the refinancing required issuing shares and warrants equal to 39% of the share count by our math, and management still has no regulatory fix for the LOTIS-5 trial after the FDA raised safety concerns.
The question now is whether the LOTIS-7 combination with Roche's glofitamab can avoid the fatal infection imbalance that stalled the LOTIS-5 trial. Either mandatory preventive antibiotics kept fatal side effects low across all 100 patients, or a repeat infection signal undermines Zynlonta's expansion into earlier lines of treatment. Full safety data at the December hematology meeting will settle it.
🐂 Bull Case
Refinancing Extends Cash Into 2029 With Dilution
ADC Therapeutics carried heavy debt and strict cash rules that threatened its ability to fund future trials. Chief executive Ameet Mallik said the biotech group made progress toward strengthening its balance sheet and increasing strategic options. While this deal solves the near-term cash crunch, it also brings major dilution for existing shareholders.
In October, management raised $86.6 million in gross proceeds ($76 million net) by selling 12.9 million shares and 48 million nearly free warrants to healthcare funds. The Swiss company used the cash to pay down its term loan, which "reduced outstanding principal by $68.5 million to $50 million, eliminated scheduled principal amortization and removed the minimum liquidity covenant". It also amended its royalty deal "to eliminate a $150 million change-of-control payment".
This matters because removing the cash floor and pushing the remaining $50 million loan payment to August 2029 extends the cash runway into 2029. Removing the $150 million buyout fee also makes the drugmaker easier to acquire, but the new shares and warrants expand the Q3 share count by 39% by our math.
What to watch: how management funds the planned late-stage trial for its drug combination in the second half of 2027. Funding that large study alone would test the new 2029 cash timeline.
Research Cuts Lowered Quarterly Losses and Burn
The cancer drugmaker has cut staff twice in the past year, including a 17% workforce reduction in June 2026, to lower its cash burn while its main trials finish enrollment.
Those cuts reduced operating expenses excluding one-offs by 29% from a year ago to $32.0 million. Research and development spending—the cost of running clinical trials and lab work—fell 45% to $14.7 million, dropping by 95 percentage points of revenue by our math. Selling and marketing costs also declined 19% to $8.7 million, or 25 percentage points of revenue, on lower advertising.
Because trial spending dropped so sharply, net loss excluding one-offs narrowed to $8.8 million from $25.5 million a year ago. Quarterly cash use was $29.9 million, but that included $13 million in one-time severance and retention payouts, leaving underlying cash burn at $16.9 million by our math.
What to watch: fourth-quarter operating expenses excluding one-offs. A further drop will show whether the promised $10 million in annual savings from the June layoffs is fully in place.
LOTIS-7 and Lymphoma Data Advance Toward December
With its first combination study facing regulatory hurdles, ADC Therapeutics relies on LOTIS-7—a trial pairing its blood cancer drug Zynlonta with Roche's antibody glofitamab—and smaller academic studies to reach earlier-stage patients.
Chief medical officer Mohamed Zaki said the upcoming presentations at the December hematology meeting highlight Zynlonta's potential in blood cancers, adding, "We plan to use these findings to guide our clinical development priorities and regulatory strategy." In 97 evaluable LOTIS-7 patients, 88.7% responded to treatment and 75.3% saw their cancer disappear completely. In a separate 43-patient study in marginal zone lymphoma, a slower-growing blood cancer, 93% responded and 74.4% achieved a complete response.
These high response rates matter because they could support inclusion in national treatment guidelines in 2027, which allows doctors to prescribe the drug with insurance coverage before formal approval.
What to watch: the fatal side-effect and severe infection rates for the full 100-patient LOTIS-7 group at the December conference. A low rate will confirm that preventive antibiotics fixed the infection risk.
🐻 Bear Case
Sales Rebound Laps an Easy Quarter
Zynlonta is currently approved only for diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer, after two or more prior treatments. Chief executive Ameet Mallik said "we continue to deliver on sales while focusing on opportunities to expand ZYNLONTA's role in the treatment of B-cell malignancies to drive growth."
Net product revenue rose 33.4% from a year ago and 12.7% from last quarter to $21.0 million, which the company attributed to higher sales volume. However, the third quarter of 2025 was the lowest sales quarter of the past two years at $15.8 million, making the year-over-year comparison unusually easy.
That context cuts against management's growth framing because quarterly sales have stayed inside a tight $15.8 million to $22.3 million band for two years, and the $21.0 million result remains below the $22.3 million recorded in late 2025. Without new approvals, third-line usage is not breaking out.
What to watch: fourth-quarter Zynlonta product revenue against the $22.3 million comparison from late 2025. A drop back below $20 million would show the third-quarter gain was just ordering timing.
FDA Safety Concerns Still Cloud LOTIS-5
LOTIS-5 is the Phase 3 trial combining Zynlonta with rituximab that was meant to confirm Zynlonta's current accelerated approval and expand its use into second-line patients. In August, US regulators raised substantial concerns because fatal side effects occurred in 13.2% of patients on the Zynlonta combination versus 4.6% in the control group.
Three months later, the drugmaker still offered no filing date or agreed path forward, listing "serious concerns related to the LOTIS-5 trial results raised by the FDA at the recent pre-sBLA submission meeting" among its ongoing risks. Meanwhile, regulatory timelines slipped across the pipeline: Breakthrough Therapy Designation filings for LOTIS-7 and marginal zone lymphoma, previously planned for 2026, moved to 2027, with guideline submissions stretching through late 2027.
This delay matters because any revenue from earlier-stage patients depends on guideline listings and approvals, leaving a long gap before new sales arrive.
What to watch: the full LOTIS-5 presentation in December and any FDA update on whether the trial can still verify clinical benefit for the existing third-line approval.
Staff Shifts and Royalties Weigh on Unit Economics
Even as trial costs fall, the ongoing cost of manufacturing Zynlonta and servicing its royalty financing continues to weigh on the business. In the third quarter, cost of product sales—the direct expense of making the drug—rose 65% from a year ago to $2.0 million, climbing by 1.8 percentage points to 9.4% of product sales by our math. The company said the increase came from shifting staff costs "from research and development clinical supply activities to commercial manufacturing activities".
At the same time, the balance sheet still carries a $303.5 million deferred royalty obligation to HealthCare Royalty Partners, which generated $9.3 million in non-cash interest expense this quarter and left shareholders' deficit at $249.2 million.
What to watch: cost of product sales as a percentage of product revenue in the fourth quarter, which will show whether manufacturing margins stabilize near 90%.
👓 Other Themes
Japanese Partner Files for Zynlonta Approval
ADC Therapeutics relies on partners to sell Zynlonta outside its core markets. During the quarter, Japanese partner Tanabe Pharma submitted a marketing application to Japan's health ministry for third-line or later DLBCL and signed an exclusive deal with Nippon Shinyaku to commercialize the drug there. The filing sets up potential regulatory and commercial milestone payments for the Swiss biotech, though the release did not disclose the dollar amounts or timing.
💲 Other KPIs
Cash fell by $29.9 million from the second quarter, down from $261.3 million at the end of 2025 as operations and $13 million in one-time severance payouts consumed funds. Including the October stock sale and debt paydown, cash stood at $196 million on a pro forma basis.
General and administrative costs—spending on legal, executive, and back-office support—rose 29.0% from a year ago and 10.7% from the second quarter. The Swiss drugmaker said higher professional fees, cash retention bonuses, and stock-based pay outweighed lower regular wages following the June layoffs.
The average share count rose 13.9% from 136.4 million a year ago because of stock sales completed in the second half of 2025. This third-quarter figure does not yet include the 12.9 million shares and 48 million penny warrants issued in the October 2026 refinancing.
🔮 Guidance
Raised. Management extended its expected cash timeline by roughly a year, into 2029, following the October refinancing and stock sale. Previously, the outlook reached at least into 2028 and required dipping into cash formerly restricted by loan covenants. Eliminating scheduled debt payments and cutting trial expenses lowered the ongoing cash requirement.
Unchanged. The biotech group still expects revenue to grow in 2027, without giving a dollar range. Because the company plans to submit LOTIS-7 data to treatment guidelines in the first quarter of 2027 and marginal zone lymphoma data in the second half of 2027, any 2027 growth depends on doctors adopting those combinations after guideline inclusion.
❓ Key Questions
What is the fatal side-effect rate in LOTIS-7?
The company reported an 88.7% response rate in 97 patients from the LOTIS-7 trial, but it did not disclose how many patients suffered fatal side effects or severe infections. That safety figure in December will determine if the combination avoids LOTIS-5's regulatory trouble.
How will the FDA treat the LOTIS-5 application?
After regulators raised serious concerns over fatal infections in the LOTIS-5 confirmatory trial in August, management still has not provided a new filing timeline. Investors need to know if a restricted label is possible or if the existing third-line approval is at risk.
Who will pay for the LOTIS-7 Phase 3 trial?
Management plans to start a Phase 3 study of Zynlonta plus glofitamab in the second half of 2027. Because large pivotal trials are expensive, the company needs to clarify whether Roche will co-fund the study or if current cash must cover it.
What drove the $2.5 million royalty liability reduction?
ADC Therapeutics recorded another $2.5 million in non-cash income from lowering its estimated future royalty payments to HealthCare Royalty Partners, bringing the nine-month adjustment to $8.9 million. Management has not explained which internal revenue forecasts it reduced to trigger this accounting gain.